Hematologic Cancer Clinical Trials

BMS CA204008: Prospective Research Assessment in Multiple Myeloma: an OBservationaL Evaluation (PREAMBLE)

Learn more by contacting the Pottstown Hospital Clinical Research Office at 610-327-7544.

ECOG-ACRIN EAA173: Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM).

The purpose of this study is to determine whether patients with high-risk smoldering multiple myeloma when treated with daratumumab in addition to lenalidomide and dexamethasone live longer when compared to patients with high-risk smoldering multiple myeloma treated with lenalidomide and dexamethasone.

Learn more about the ECOG-ACRIN EAA173 trial or call the Reading Hospital Protocol Office at 484-628-8193.

ECOG-ACRIN EAA181: Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation.

The purpose of this study is to determine if, after receiving 9 cycles of the usual treatment with three drugs (daratumumab, lenalidomide and dexamethasone), adding bortezomib to the three drugs for the second set of 9 treatment cycles (cycles 10-18) could be more effective in shrinking your cancer or preventing it from returning, compared to continuing on the same three-drug combination for another 9 treatment cycles.

Learn more about the ECOG-ACRIN EAA181 trial or call the Reading Hospital Protocol Office at 484-628-8193.

EMN29: A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM).

The purpose of this study is to compare and evaluate the effectiveness and safety of the experimental treatment of selinexor in combination with pomalidomide and dexamethasone, compared to the effectiveness and safety of the standard treatment of elotuzumab in combination with pomalidomide and dexamethasone.
 

Learn more about the EMN29 trial or call the Reading Hospital Protocol Office at 484-628-8193.

Connect® Myeloid Disease Registry: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry.

The three main purposes of this study are: (1) to use the information collected to help better understand patterns for diagnosis, treatment and outcomes, including disease progression and survival, in patients with myeloid diseases; (2) to use the information to help better understand patterns for the quality of life in patients with myeloid diseases; and, (3) to use the results of this study to provide information on the effect different treatments have on a patient’s disease and on their quality of life.

Learn more about the Connect® Myeloid Disease Registry or call the Reading Hospital Protocol Office at 484-628-8193.

Genentech ML43389: An Open-Label, Multicenter, Phase II Trial Evaluating the Safety, Efficacy, and Pharmacokinetics of Subcutaneous Mosunetuzumab Monotherapy in Patients with Select B-Cell Malignancies (MorningSun).

The purpose of this study is to test the effects, good or bad, of mosunetuzumab on patients with untreated  follicular lymphoma (FL), untreated diffuse large B-cell lymphoma (DLBCL), untreated marginal zone lymphoma (MZL), relapsing/recurring [refractory] mantle cell lymphoma (R/R MCL), and relapsing/recurring [refractory] Richter’s transformation (R/R RT) or relapsing/recurring [refractory] transformed follicular lymphoma (R/R tFL).

Learn more about the Genentech ML43389 trial or call the Reading Hospital Protocol Office at 484-628-8193.

AbbVie M23-362: A Phase 2, Open-Label Trial to Evaluate Safety of Epcoritamab Monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma (Previously Grade 1-3a) when Administered in the Outpatient Setting.

The purpose of this study is to determine if epcoritamab can be safely given without subjects needing to be admitted to the hospital (which usually means staying in the hospital overnight).

Learn more about the AbbVie M23-362 trial or call the Reading Hospital Protocol Office at 484-628-8193.